Video Experimental Relacionado
Updated: May 3, 2026
10:24
In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions
Published on: June 11, 2015
12.8K
El factor von Willebrand como objetivo para la intervención antitrombótica
1Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla Calif. 92037.
Circulation
|December 1, 1992
Resumen
Pequeños fragmentos de proteínas pueden bloquear el factor de von Willebrand.
Área de la Ciencia:
- La bioquímica es la bioquímica.
- Hematología Hematología.
- Biología Molecular Biología Molecular
Sus antecedentes:
- El factor Von Willebrand es una proteína adhesiva crucial para la formación de trombos plaquetarios bajo alta tensión de cizallamiento.
- La formación de trombos plaquetarios implica interacciones entre el factor de von Willebrand y los receptores plaquetarios de la glicoproteína Ib-IX-V y IIb-IIIa.
- La interacción de la glicoproteína Ib-IX-V inicia la activación plaquetaria, un requisito previo para la agregación estable a través de la glicoproteína IIb-IIIa.
Objetivo del estudio:
- Investigar el potencial de pequeños fragmentos recombinantes para inhibir la unión del factor de von Willebrand a la glicoproteína Ib.
- Explorar un nuevo enfoque selectivo para la terapia antitrombótica.
Principales métodos:
- Se utilizaron pequeños fragmentos recombinantes diseñados para atacar el dominio funcional específico del factor de von Willebrand que se une a la glicoproteína Ib.
- Se evaluó el efecto inhibidor de estos fragmentos en las interacciones entre el factor de von Willebrand y las plaquetas.
Principales resultados:
- Se ha demostrado que pequeños fragmentos recombinantes pueden inhibir eficazmente la unión del factor de von Willebrand a la glicoproteína Ib.
- Se identificó un dominio funcional específico dentro del factor von Willebrand responsable de esta interacción.
Conclusiones:
- Los pequeños fragmentos recombinantes dirigidos a la interacción entre el factor de von Willebrand y la glicoproteína Ib ofrecen una estrategia antitrombótica selectiva prometedora.
- Este enfoque puede conducir a nuevas opciones terapéuticas para prevenir la trombosis.
Videos de Conceptos Relacionados
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
10.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.9K
01:16Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482